EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer

BACKGROUND: In early estrogen receptor (ER)-positive/HER2-negative breast cancer, the decision to administer chemotherapy is largely based on prognostic criteria. The combined molecular/clinical EndoPredict test (EPclin) has been validated to accurately assess prognosis in this population. In this s...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Dubsky, P., Filipits, M., Jakesz, R., Rudas, M., Singer, C. F., Greil, R., Dietze, O., Luisser, I., Klug, E., Sedivy, R., Bachner, M., Mayr, D., Schmidt, M., Gehrmann, M. C., Petry, C., Weber, K. E., Kronenwett, R., Brase, J. C., Gnant, M.
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2013
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3574544/
https://ncbi.nlm.nih.gov/pubmed/23035151
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mds334
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados